Big-time pharma mergers have had a mixed track record, with large
combinations often leading to significant cost reductions (and firings)
in sales and administration but at the cost of large disruptions to
R&D. Pfizer (NYSE: PFE ) is apparently not afraid to give it another try, as word came out over the Easter holiday that the company has approached AstraZeneca (NYSE: AZN ) with a $100 billion-plus bid to acquire this once-struggling pharma giant.
Time will tell if Pfizer can coax AstraZeneca to the negotiating
table and seal a deal, but such a combination may not be as big of a
risk for Pfizer as it may immediately seem.
Continue here:
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
No comments:
Post a Comment